Stoke Therapeutics Equity 2024

Stoke Therapeutics Aktienanalyse

What does Stoke Therapeutics do?

Stoke Therapeutics Inc is a biopharmaceutical company founded in 2018 by experienced scientists to develop innovative therapeutic approaches for rare genetic diseases. The company's headquarters is located in Bedford, Massachusetts, and since its inception, it has continuously invested to expand its business and its development process. In 2019, the company announced a financing round of $90 million to advance the development of its pipeline and clinical trials. Stoke Therapeutics specializes in the development of therapeutics for the treatment of rare genetic diseases caused by mutations in haploinsufficiency genes. These diseases are caused by mutations in one of the two genes that code for a specific protein. Since a single defective gene is not sufficient to maintain the normal functions of a protein, serious health problems arise. Stoke's therapeutics aim to replace the missing gene product by targeted stimulation of the healthy gene. This is achieved through the development of antisense oligonucleotide-based therapeutics. Antisense oligonucleotides are small DNA-like molecules that are able to address, recognize, and bind to specific genes. By binding to the healthy gene, they can promote its expression and thereby replace the missing protein. The company's pipeline currently includes a range of products at various stages of development, including preclinical and clinical trials. The following products are the most important: STK-001: A product developed for the treatment of severe forms of Dravet syndrome. Dravet syndrome is a rare genetic disease characterized by seizures, developmental delays, and other neurological symptoms. STK-002: A product for the treatment of haploinsufficiency in STING1-associated vasculopathic syndrome (SAVS). SAVS is a rare genetic disease characterized by cardiovascular disorders and increased susceptibility to infections. STK-005: A product for the treatment of haploinsufficiency in adrenoleukodystrophy (ALD). ALD is a rare disease characterized by inflammatory and degenerative changes in the nervous system. Due to its innovative technology and focus on rare genetic diseases, Stoke Therapeutics has attracted the attention of many investors and potential partners. In 2020, the company entered into collaboration agreements with Roche Holdings and Ribometrix Inc to accelerate the development and commercialization of its therapeutics. Overall, Stoke Therapeutics has a promising future as it is able to provide a much-needed treatment option for patients with rare genetic diseases who currently have no effective therapies available. Stoke Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Stoke Therapeutics's Equity

Stoke Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Stoke Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Stoke Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Stoke Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Stoke Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Stoke Therapeutics stock

What is the equity of Stoke Therapeutics this year?

Stoke Therapeutics has equity of 159.57 M USD this year.

What was the equity of Stoke Therapeutics compared to the previous year?

The equity of Stoke Therapeutics has increased/decreased by -13.66% decreased compared to the previous year.

What impact does a high equity have on investors of Stoke Therapeutics?

A high equity is advantageous for investors of Stoke Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Stoke Therapeutics?

A low equity can be a risk for investors of Stoke Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Stoke Therapeutics affect the company?

An increase in equity of Stoke Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Stoke Therapeutics affect the company?

A reduction in equity of Stoke Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Stoke Therapeutics?

Some factors that can affect the equity of Stoke Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Stoke Therapeutics so important for investors?

The equity of Stoke Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Stoke Therapeutics take to change the equity?

To change equity, Stoke Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Stoke Therapeutics pay?

Over the past 12 months, Stoke Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Stoke Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Stoke Therapeutics?

The current dividend yield of Stoke Therapeutics is .

When does Stoke Therapeutics pay dividends?

Stoke Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Stoke Therapeutics?

Stoke Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Stoke Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Stoke Therapeutics located?

Stoke Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Stoke Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Stoke Therapeutics from 10/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.

When did Stoke Therapeutics pay the last dividend?

The last dividend was paid out on 10/6/2024.

What was the dividend of Stoke Therapeutics in the year 2023?

In the year 2023, Stoke Therapeutics distributed 0 USD as dividends.

In which currency does Stoke Therapeutics pay out the dividend?

The dividends of Stoke Therapeutics are distributed in USD.